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Abstract: Activating mutations in epidermal growth factor receptor 
(EGFR) are present in a subset of lung cancers, and predict sensitiv-
ity to EGFR tyrosine kinase inhibitors. Acquisition of EGFR T790M 
is the most common mechanism of resistance to EGFR tyrosine 
kinase inhibitors and rarely is seen before treatment. Germline EGFR 
T790M mutations have been reported, although the penetrance and 
clinical significance of this mutation is unknown. We describe the 
identification of a patient with an EGFR T790M germline mutation 
and subsequent germline testing in her unaffected family members. 
Genetic testing revealed two additional EGFR T790M germline car-
riers, one of which was subsequently diagnosed with metastatic lung 
adenocarcinoma.
(J Thorac Oncol. 2014;9: 554–558)
Somatic, activating mutations in epidermal growth fac-tor receptor (EGFR; Exon 19 deletions, as well as point 
mutations in L858R, G719, L861) promote oncogenesis in 
a specific subset of lung adenocarcinomas.1 In patients with 
EGFR mutant lung cancer, EGFR tyrosine kinase inhibi-
tors (TKIs) are more effective than cytotoxic chemotherapy 
although patients develop resistance after a median of 12 
to 16 months on therapy.2 The most common mechanism 
of resistance to EGFR TKIs is the acquisition of the EGFR 
T790M point mutation, which occurs in 60% of patients.3,4 
De novo EGFR T790M mutations are rarely seen by stan-
dard genotyping methods, and occur in less than 1% of all 
lung cancers and approximately 2% of all EGFR mutant lung 
cancers.5
Germline EGFR T790M mutations have been reported 
in association with familial non–small-cell lung cancer 
although the degree of risk, penetrance, and the resultant clini-
cal syndrome has not been fully elucidated.6 Here we describe 
the results of comprehensive molecular testing on multiple 
synchronous lung tumors in a patient who had genetic test-
ing revealing a germline EGFR T790M mutation. The identi-
fication of the germline mutation in the proband led to cohort 
testing of her unaffected relatives, resulting in the discov-
ery of two additional EGFR T790M germline carriers, one 
of whom was subsequently diagnosed with metastatic lung 
adenocarcinoma.
The index case is a 44-year-old never-smoker with no 
family history of lung cancer, who initially presented with 
enlarged axillary lymph nodes. Imaging revealed multiple 
bilateral ground-glass opacities within the lungs. She under-
went right-sided wedge biopsies, and biopsies of the right 
middle lobe and right lower lobe revealed well-differentiated 
adenocarcinoma. The right middle lobe nodule harbored both 
an EGFR T790M mutation and a 15bp EGFR exon 19 dele-
tion. She underwent a left-sided thoracotomy with multiple 
wedge biopsies of the left lower and left upper lobes to further 
define the extent of her disease. Four discrete left lower lobe 
(LLL) nodules and one left upper lobe (LUL) nodule were 
excised and were consistent with structurally distinct adeno-
carcinomas, indicating synchronous primary lung cancers 
rather than metastatic disease (Fig. 1). The EGFR T790M 
mutation was identified in all samples upon routine diagnostic 
molecular testing. Four samples (3 from the LLL, 1 from the 
LUL) harbored an EGFR L858R point mutation. One sample 
from the LLL had a 3bp deletion in EGFR exon 19 found 
using fragment analysis and confirmed by Sanger sequencing 
(Table 1).
Because of a strong family history of cancer (Table 2) 
and her new diagnosis of multiple primary lung cancers, she 
was referred to clinical genetics for evaluation for a germline 
susceptibility to cancer. She had testing performed on periph-
eral blood for both EGFR*2369C to T (T790M) and BRCA1/2 
because of her family history of breast and ovarian cancer. 
She tested positive for the germline EGFR T790M mutation, 
and was also found to have a BRCA 2 variation of uncertain 
significance at L459S (1604 T to C). She is followed regu-
larly with interval computed tomography scans that indicate 
stable bilateral pulmonary nodules and ground-glass opacities 
(Fig. 2, Patient A). She continues to be monitored expectantly 
on no systemic therapy.
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Further molecular analysis of this patient’s synchro-
nous tumors was performed to gain insight on the molecular 
progression from a germline susceptibility mutation, EGFR 
T790M, to clinically evident malignancy. Massively parallel 
sequencing7 was performed of all exons of 230 cancer genes 
(see Supplementary Data for gene list, Supplemental Digital 
Content 1, http://links.lww.com/JTO/A498). The technique 
used to sequence exons of genes of interest7 and the technical 
implementation of an oncogene screening profile8 have been 
described previously. Exonic DNA was captured via solution-
based hybrid selection9 and sequenced on the Illumina HiSeq 
platform (Illumina, San Diego, CA). The sequencing data were 
analyzed for base mutations, insertions, deletions, copy num-
ber alterations, and genomic rearrangements in all target genes.
A peripheral blood sample and three tumor samples (T-2, 
T-3, T-4) yielded adequate DNA for analysis on this platform. 
The EGFR T790M variant was detected in all three tumor 
samples (T-2, T-3, T-4) and the normal blood at allele frequen-
cies of 48%, 51%, 48%, and 52%, respectively, as expected 
for a germline variant. The BRCA2 L459S germline variant 
was identified in the peripheral blood normal tissue in 413 of 
868 reads. T-2 had an additional ARID1A K1938N somatic 
point mutation at an allele frequency of 19%, T-3 and T-4 had 
EGFR L858R somatic point mutations at allele frequencies 
of 11% and 16%, respectively. No additional insertions, dele-
tions, point mutations or rearrangements were identified in the 
230 cancer genes analyzed (Fig. 3).
After our proband was identified as a carrier of a germ-
line EGFR T790M mutation, her mother was referred to clini-
cal genetics for germline EGFR T790M testing to ascertain 
whether the mutation in the proband was a de novo event or an 
inherited EGFR 2369C>T (T790M) germline mutation. After 
the initial clinical genetics evaluation, the proband’s mother 
was diagnosed with metastatic lung adenocarcinoma present-
ing with bilateral ground-glass opacities and pulmonary nod-
ules similar to the proband. She returned to clinical genetics 
and was informed of her positive EGFR 2369C>T (T790M) 
germline mutation. BRCA 2 testing for the variation of uncer-
tain significance at L459S was not performed because of lack 
of insurance coverage for the requested test.
Because of the T790M germline mutation found in 
two family members, we offered all interested family mem-
bers genetic counseling and germline testing. Eleven family 
FIGURE 1.  Hematoxylin and eosin 
stained sections of six tumors at 
intermediate magnification show 
adenocarcinomas of mixed phe-
notype with varying proportions 
of lepidic, bronchoalveolar, acinar, 
and papillary patterns. All tumors 
appeared structurally distinct, favor-
ing separate primaries.
TABLE 1.  Synchronous Tumors and Resultant Diagnostic 
Molecular Testing
Tumor Standard Molecular Path NGS Mutation Profile
T-1 (RML) EGFR T790M, 15bp exon 
19 del
T-2 (RUL) EGFR T790M EGFR T790M, ARID1A K1938N
T-3 (LLL) EGFR T790M, L858R EGFR T790M, L858R
T-4 (LLL) EGFR T790M, L858R EGFR T790M, L858R
T-5 (LLL) EGFR T790M, L858R
T-6 (LLL) EGFR T790M, 3bp exon 
19 del
T-7 (LUL) EGFR T790M, L858R
TABLE 2.  Family History of Proband
Family Member Breast Ovarian Cancer Pancreatic Cancer Prostate Cancer Leukemia
Father X
Maternal aunt #1 X (premenopausal)
Maternal aunt #2 X (premenopausal) X
Maternal aunt #3 X (postmenopausal)
Maternal aunt #4 X
Maternal cousin X (premenopausal)
Maternal grandfather X
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members (Fig. 4) came to an informational session where vol-
untary germline testing was offered. Testing was performed 
on seven family members. Of the seven people tested, the pro-
band’s daughter was the only one found to carry the EGFR 
2369C>T (T790M) germline mutation (Table 3).
Germline EGFR T790M mutation carriers need to 
be prospectively studied to better understand the clinical 
implications of this germline mutation. In mouse models, 
the presence of the EGFR T790M mutation induces tumor 
formation, suggesting that the mutation is sufficient for 
oncogenesis.10
Clinically, the presence of germline EGFR T790M 
is associated with the development of lung adenocarci-
noma, although the penetrance and clinical significance of 
FIGURE 2.  Serial interval computed 
tomography scans of patients with 
germline epidermal growth factor 
receptor T790M.
FIGURE 3.  The results from next 
generation sequencing on tumor 2 
(T-2), tumor 3 (T-3), tumor 4 (T-4), 
and normal blood. The EGFR T790M 
point mutation was identified in all 
samples. In addition to EGFR T790M, 
T-2 had evidence of an ARID1A 
K1938N mutation, and T-3 and T-4 
had evidence of an EGFR L858R point 
mutation. EGFR, epidermal growth 
factor receptor.
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this mutation is not fully elucidated. Screening for germline 
T790M mutations in unselected populations has not been fruit-
ful.11,12 However, germline EGFR T790M mutations are pres-
ent in approximately 50% of all patients with baseline EGFR 
T790M identified in their pretreatment tumor specimens.13 
We have recommended that all patients with baseline EGFR 
T790M identified in their lung tumor tissue be referred to 
clinical genetics to discuss EGFR T790M germline testing.13
In our practice, patients with germline EGFR T790M 
mutations can present radiographically with bilateral ground-
glass opacities and pulmonary nodules (Fig. 2), and often have 
an indolent disease course. Two of our four patients with con-
firmed germline EGFR T790M are being monitored expec-
tantly and have gone as long as six years off treatment with 
stable disease. This is consistent with cell line data that EGFR-
mutant cell lines that acquire EGFR T790M mutation display 
indolent growth.14 However, this is not uniformly so, as the 
other two patients had more aggressive, widely metastatic dis-
ease treated with chemotherapy and both eventually died from 
their disease. All four patients with germline EGFR T790M 
were never-smokers, and information regarding response to 
erlotinib in germline EGFR T790M carriers is not available as 
none were treated with erlotinib monotherapy.
Molecular testing of our patient revealed few concur-
rent somatic mutations. Besides the EGFR exon 19 deletion 
identified in one lesion, concurrent EGFR L858R and EGFR 
T790M mutations were identified in two of the samples, 
which has been previously described.6 Another sample had a 
concurrent ARID1A mutation, which was recently reported in 
lung adenocarcinoma and is known to be oncogenic in other 
malignancies.15 Newer TKIs, such as AP26113 and CO-1686, 
have selectivity for EGFR T790M over wild-type EGFR 
and are currently in early-phase studies (NCT01449461 and 
NCT01526928, respectively). Chemoprevention using an 
EGFR T790M selective agent could be studied in unaffected 
T790M germline carriers, similar to the use of tamoxifen in 
the breast cancer high-risk population. In addition, screening 
computed tomography scans for patients with germline EGFR 
T790M mutations may be warranted as is recommended for 
other high-risk populations.
The highest incidence of germline EGFR T790M 
mutations have been identified in patients with pretreatment 
somatic EGFR T790M mutations, and continued referral 
of these patients to clinical genetics is important to discuss 
germline testing. Carriers of EGFR T790M need to be fol-
lowed prospectively to learn the clinical significance of this 
germline mutation. Other somatic mutations (EGFR L858R, 
EGFR exon 19 deletions, ARID1A K1938N) occur concur-
rently with EGFR T790M, and analysis of these germline 
carriers may provide insight into the oncogenic process from 
germline mutation carrier to clinically evident malignancy. 
The ultimate goal of this line of research is to understand the 
cancer risk associated with this germline mutation, identify 
FIGURE 4.  Pedigree with labeled family members and germline testing results.
TABLE 3.  Germline Testing Results
Location on  
Pedigree
Relationship to 
Proband Tested (Result)
1 Mother Yes (positive)
2 Daughter Yes (positive)
3 Sister Yes (negative)
4 Brother Yes (negative)
5 Niece Yes (negative)
6 Maternal uncle Yes (negative)
7 First cousin Yes (negative)
8 First cousin Yes (negative)
9 First cousin No
10 First cousin No
Not pictured Second cousin No
Not pictured Third cousin No
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carriers, and provide them with interventions that will reduce 
their risk of cancer-related mortality.
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